# Biotech Daily Digest â€” 2026-02-23

**29 items from 3 sources**

## Summary by Source

- Endpoints News: 6 items
- Fierce Biotech: 6 items
- arXiv q-bio: 17 items


## Endpoints News

- **[Roche to stop work on bone health treatment for Duchenne](https://endpoints.news/roche-to-stop-work-on-bone-health-treatment-for-duchenne/)**  
  _Mon, 23 Feb 2026 14:40:19 +0000_  
  Roche is no longer recruiting patients for a Phase 2 trial studying its immune disease drug Enspryng in Duchenne muscular dystrophy, and will end work developing the treatment for bone health in those patients.  ...

- **[Merck reorganizes; Blackstone to fund trials for J&J drug](https://endpoints.news/merck-reorganizes-blackstone-to-fund-trials-for-jj-drug/)**  
  _Mon, 23 Feb 2026 14:25:25 +0000_  
  Plus, news about Bristol Myers Squibb's Reblozyl:

 ðŸ”€ A revamp at Merck: The New Jersey pharma giant announced on Monday that itâ€™s splitting its human health organization in two ...

- **[Gossamer Bioâ€™s potential Winrevair competitor fails pivotal trial](https://endpoints.news/gossamer-bios-pivotal-pah-trial-fails/)**  
  _Mon, 23 Feb 2026 13:00:43 +0000_  
  Gossamer Bio needed a success in the Phase 3 trial of its drug for the lung disease pulmonary arterial hypertension. But it did not get one.

 The PROSERA trial aimed to prove that after six ...

- **[Gilead to acquire cell therapy partner Arcellx for $7.8B](https://endpoints.news/gilead-to-acquire-cell-therapy-partner-arcellx-for-7-8b/)**  
  _Mon, 23 Feb 2026 11:06:14 +0000_  
  Gilead Sciences is buying its CAR-T collaborator Arcellx as its closely-watched multiple myeloma cell therapy nears potential approval and launch.

 The deal is worth $7.8 billion, when calculated from $115 per ...

- **[Novo Nordiskâ€™s CagriSema beaten by Lillyâ€™s Zepbound in head-to-head obesity trial](https://endpoints.news/novo-nordisks-cagrisema-beaten-by-lillys-zepbound-in-head-to-head-obesity-trial/)**  
  _Mon, 23 Feb 2026 10:03:49 +0000_  
  Novo Nordiskâ€™s GLP-1/amylin combo drug CagriSema was not as good as Eli Lillyâ€™s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday.

 Patients in the REDEFINE 4 ...

- **[MoonLake has 'confidence' ahead of FDA submission, discloses mid-stage arthritis win](https://endpoints.news/moonlake-has-confidence-ahead-of-fda-submission-discloses-mid-stage-arthritis-win/)**  
  _Sun, 22 Feb 2026 16:00:51 +0000_  
  MoonLake Immunotherapeuticsâ€™ only investigational drug showed a clinically meaningful benefit in patients with an aggressive form of inflammatory arthritis, according to Phase 2 data the company shared with Endpoints News on Sunday.

 While that news ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/generate-plans-425m-ipo-bankroll-antibodys-phase-3-asthma-trials" hreflang="en">Generate plans $425M IPO to bankroll antibodyâ€™s phase 3 asthma trials</a>](https://www.fiercebiotech.com/biotech/generate-plans-425m-ipo-bankroll-antibodys-phase-3-asthma-trials)**  
  _Feb 23, 2026 9:00am_  
  Generate:Biomedicines is hoping to raise up to $425 million via an IPO, with the proceeds expected to bankroll its lead antibody through respiratory disease trials.

- **[<a href="https://www.fiercebiotech.com/sponsored/iregene-hits-dual-global-firsts-us-patient-dosed-phase-iia-nouvneu001-parkinsons-and" hreflang="en">iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinsonâ€™s and First Enrollment in Chinaâ€™s Randomized MSA Trial for NouvNeu004</a>](https://www.fiercebiotech.com/sponsored/iregene-hits-dual-global-firsts-us-patient-dosed-phase-iia-nouvneu001-parkinsons-and)**  
  _Feb 19, 2026 11:40am_  
  Breaking ground: iRegeneâ€™s NouvNeu001 hits first U.S. dosing in Parkinsonâ€™s Phase IIa, while NouvNeu004 starts enrollment in China MSA trial. Pushing forward off-the-shelf iPSC therapies on a global scale.

- **[<a href="https://www.fiercebiotech.com/sponsored/assessing-myelin-formation-and-therapeutic-response-using-3d-organoids" hreflang="en">Assessing Myelin Formation and Therapeutic Response Using 3D Organoids</a>](https://www.fiercebiotech.com/sponsored/assessing-myelin-formation-and-therapeutic-response-using-3d-organoids)**  
  _Feb 18, 2026 12:58pm_  
  Demyelinating diseases, including multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT) disease, present a substantial and escalating burden. Each of these conditions afflicts approximately three million individuals worldwide.

- **[<a href="https://www.fiercebiotech.com/biotech/gilead-inks-78b-arcellx-buyout-steer-car-t-jj-showdown" hreflang="en">Gilead inks $7.8B Arcellx buyout to steer CAR-T into J&amp;J showdown</a>](https://www.fiercebiotech.com/biotech/gilead-inks-78b-arcellx-buyout-steer-car-t-jj-showdown)**  
  _Feb 23, 2026 7:02am_  
  Gilead has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval.

- **[<a href="https://www.fiercebiotech.com/biotech/novos-cagrisema-loses-phase-3-battle-mounjaro-knocking-15-share-price" hreflang="en">Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price</a>](https://www.fiercebiotech.com/biotech/novos-cagrisema-loses-phase-3-battle-mounjaro-knocking-15-share-price)**  
  _Feb 23, 2026 6:35am_  
  Novo Nordiskâ€™s GLP-1/amylin combo has failed to beat Eli Lillyâ€™s Zepbound in a phase 3 weight loss study, further denting the Danish pharmaâ€™s attempts to reclaim its obesity crown.

- **[<a href="https://www.fiercebiotech.com/biotech/moonlakes-phase-2-arthritis-win-kicks-pivotal-year-il-17-nanobody" hreflang="en">MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody</a>](https://www.fiercebiotech.com/biotech/moonlakes-phase-2-arthritis-win-kicks-pivotal-year-il-17-nanobody)**  
  _Feb 23, 2026 5:11am_  
  MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a midstage win in a type of arthritis.


## arXiv q-bio

- **[GeneZip: Region-Aware Compression for Long Context DNA Modeling](https://arxiv.org/abs/2602.17739)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17739v1 Announce Type: new 
Abstract: Genomic sequences span billions of base pairs (bp), posing a fundamental challenge for genome-scale foundation models. Existing approaches largely sidestep this barrier by either scaling relatively small models to long contexts or relying on heavy multi-GPU parallelism.â€¦

- **[AgriVariant: Variant Effect Prediction using DeepChem-Variant for Precision Breeding in Rice](https://arxiv.org/abs/2602.17747)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17747v1 Announce Type: new 
Abstract: Predicting functional consequences of genetic variants in crop genes remains a critical bottleneck for precision breeding programs. We present AgriVariant, an end-to-end pipeline for variant-effect prediction in rice (Oryza sativa) that addresses the lack of crop-specifâ€¦

- **[Scaling and tuning to criticality in resting-state human magnetoencephalography](https://arxiv.org/abs/2602.17820)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17820v1 Announce Type: new 
Abstract: Scaling laws in biological neural networks have long been investigated. From 1/f noise to neuronal avalanches, evidence of scaling in brain activity has been increasingly linked to tuning to or near criticality. The concept of scaling is intimately related to the renormâ€¦

- **[Metrology of Complexity and Implications for the Study of the Emergence of Life](https://arxiv.org/abs/2602.18203)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2602.18203v1 Announce Type: new 
Abstract: One of the longest standing open problems in science is how life arises from non-living matter. If it is possible to measure this transition in the lab, then it might be possible to understand the physical mechanisms by which the emergence of life occurs, which so far hâ€¦

- **[Simple non-invasive methods for obtaining the intensity and timing of arterial pulse waves](https://arxiv.org/abs/2602.17866)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2602.17866v1 Announce Type: cross 
Abstract: Contraction of the left ventricle of the heart increases aortic root blood pressure (P), diameter (D) and blood velocity (U). When contraction diminishes, all three properties decrease. These perturbations propagate down the systemic arteries as the S wave and D wave,â€¦

- **[Emergence of generic first-passage time distributions for large Markovian networks](https://arxiv.org/abs/2602.18265)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2602.18265v1 Announce Type: cross 
Abstract: First-passage times are often the most relevant aspect of a complex Markovian network, because they signify when information processing has resulted in a definite decision. Previous studies have shown that for kinetic proofreading networks in the limit of large networâ€¦

- **[Leakage and Second-Order Dynamics Improve Hippocampal RNN Replay](https://arxiv.org/abs/2602.18401)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2602.18401v1 Announce Type: cross 
Abstract: Biological neural networks (like the hippocampus) can internally generate "replay" resembling stimulus-driven activity. Recent computational models of replay use noisy recurrent neural networks (RNNs) trained to path-integrate. Replay in these networks has been descriâ€¦

- **[Physics-informed graph neural networks for flow field estimation in carotid arteries](https://arxiv.org/abs/2408.07110)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2408.07110v2 Announce Type: replace 
Abstract: Hemodynamic quantities are valuable biomedical risk factors for cardiovascular pathology such as atherosclerosis. Non-invasive, in-vivo measurement of these quantities can only be performed using a select number of modalities that are not widely available, such as 4â€¦

- **[An Entropy-initiated Coupled-Trait ODE Framework for Modeling Longitudinal Cohort Dynamics](https://arxiv.org/abs/2506.20622)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2506.20622v3 Announce Type: replace 
Abstract: This work introduces a minimal, information-theoretic dynamical framework for modeling longitudinal cohort data using an entropy-initiated system of coupled-trait ordinary differential equations (ECTO). For each survey wave, item-level Likert responses are compresseâ€¦

- **[Critical dynamics governs deep learning](https://arxiv.org/abs/2507.08527)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2507.08527v2 Announce Type: replace 
Abstract: The rapid advances in artificial intelligence (AI) have largely been driven by scaling deep neural networks (DNNs) - increasing model size, data, and computational resources. Yet performance is ultimately governed by network dynamics. The lack of a principled undersâ€¦

- **[Ensemble-based graph representation of fMRI data for cognitive brain state classification](https://arxiv.org/abs/2508.06118)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2508.06118v2 Announce Type: replace 
Abstract: fMRI is a non-invasive technique for investigating brain activity, offering high-resolution insights into neural processes. Understanding and decoding cognitive brain states from fMRI depends on how functional interactions are represented. We propose an ensemble-basâ€¦

- **[Epidemic "momentum" and a conservation law for infectious disease dynamics](https://arxiv.org/abs/2511.01939)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2511.01939v2 Announce Type: replace 
Abstract: Infectious disease outbreaks have precipitated a profusion of mathematical models. Epidemic curves predicted by these models are typically qualitatively similar, despite distinct model assumptions, but there is no theoretical explanation for this similarity in termsâ€¦

- **[Support Graph Preconditioners for Off-Lattice Cell-Based Models](https://arxiv.org/abs/2410.04512)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2410.04512v2 Announce Type: replace-cross 
Abstract: Off-lattice agent-based models (or cell-based models) of multicellular systems are increasingly used to create in-silico models of in-vitro and in-vivo experimental setups of cells and tissues, such as cancer spheroids, neural crest cell migration, and liver lâ€¦

- **[Co-Evolution-Based Metal-Binding Residue Prediction with Graph Neural Networks](https://arxiv.org/abs/2502.16189)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2502.16189v2 Announce Type: replace-cross 
Abstract: Understanding protein-metal interactions is central to structural biology, with metal ions being vital for catalysis, stability, and signal transduction. Predicting metal-binding residues and metal types remains challenging due to the structural and evolutionaâ€¦

- **[Generative Distribution Embeddings: Lifting autoencoders to the space of distributions for multiscale representation learning](https://arxiv.org/abs/2505.18150)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2505.18150v2 Announce Type: replace-cross 
Abstract: Many real-world problems require reasoning across multiple scales, demanding models which operate not on single data points, but on entire distributions. We introduce generative distribution embeddings (GDE), a framework that lifts autoencoders to the space ofâ€¦

- **[Nonlinear Public Goods Game in Dynamical Environments](https://arxiv.org/abs/2510.10259)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2510.10259v2 Announce Type: replace-cross 
Abstract: The evolutionary mechanisms of cooperative behavior represent a fundamental topic in complex systems and evolutionary dynamics. Real-world collective interactions, particularly in multi-agent systems, are often characterized by behavior-dependent mechanism swiâ€¦

- **[Simple 3D Pose Features Support Human and Machine Social Scene Understanding](https://arxiv.org/abs/2511.03988)**  
  _Mon, 23 Feb 2026 00:00:00 -0500_  
  arXiv:2511.03988v2 Announce Type: replace-cross 
Abstract: Humans effortlessly recognize social interactions from visual input, yet the underlying computations remain unknown, and social interaction recognition challenges even the most advanced deep neural networks (DNNs). Here, we hypothesized that humans rely on 3Dâ€¦
